What is new in nanoparticle‐based photoacoustic imaging?

Lemaster, Jeanne E.; Jokerst, Jesse V.

doi:10.1002/wnan.1404

Cited by 104 publications

(107 citation statements)

References 74 publications

(133 reference statements)

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…reported that small nanoparticles are preferable for photothermal therapy because light is mainly adsorbed by the particles and, thus, is efficiently converted into heat for cell and tissue destruction [51]. However, particles smaller than ~10 nm are easily cleared from systemic circulation via the kidneys [52]. Fig 1c shows the absorbance spectra of AXT in saline as a solvent.…”

Section: Resultsmentioning

confidence: 99%

Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy

Nguyen

Kim

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

The photothermal effect of a marine-oriented xanthophyll carotenoid, astaxanthin (AXT), was characterized based on its potential absorption of visible laser light and conversion of optical light energy into heat for thermal treatment. As an antioxidant and anticancer agent, AXT extracted from marine material can be utilized for photothermal therapy due to its strong light absorption. The current study investigated the feasibility of the marine-based material AXT to increase the therapeutic efficacy of chemo-photothermal therapy (PTT) by assessing photothermal sessions in both cells and tumor tissues. A quasi-cw Q-switched 80 W 532 nm laser system was utilized to induce thermal necrosis in in vitro and in vivo models. An in vitro cytotoxicity study of AXT was implemented using squamous cell carcinoma (VX2) and macrophage (246.7) cell lines. In vivo PTT experiments were performed on 17 rabbits bearing VX2 tumors on their eyes that were treated with or without intratumoral injection of AXT at a dose of 100 μl (300 μg/ml) followed by laser irradiation at a low irradiance of 0.11 W/cm2. Fluorescence microscopy images revealed cellular death via apoptosis and necrosis owing to the dual chemo-photothermal effects induced by AXT. In vivo experimental results demonstrated that the AXT-assisted irradiation entailed a temperature increase by 30.4°C after tumor treatment for 4 min. The relative variations in tumor volume confirmed that the tumors treated with both AXT and laser irradiation completely disappeared 14 days after treatment, but the tumors treated under other conditions gradually grew. Due to selective light absorption, AXT-assisted laser treatment could be an effective thermal therapy for various drug-resistant cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy

Nguyen

Kim

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Medical diagnosis and therapeutic options benefit greatly from imaging technologies that combine molecular and microscopic parameters with clinical observations; such a combination is provided by photoacoustic imaging (also known as optoacoustic imaging) . Photoacoustic imaging is a label‐free, non‐ionizing, noninvasive, high‐resolution optical imaging modality that uses optical absorption contrast and ultrasonic resolution . This technology has a high scalability and allows imaging of biological structures, ranging from molecules, organelles, cells, and tissues to entire organs and even entire small animal bodies .…”

Section: Caveats Challenges and Insights On The Diagnosis And Theramentioning

confidence: 99%

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng

Kros

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune‐based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T‐cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients. Cardiac complications represent unresolved and potentially life‐threatening conditions in cancer survivors, while effective clinical management remains quite challenging. As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer‐related survival, regardless of the oncologic prognosis. This review focuses on identifying critical research‐practice gaps, addressing real‐world challenges and pinpointing real‐time insights in general terms under the context of clinical cardiotoxicity induced by the fourth and fifth modalities of cancer treatment. The information ranges from basic science to clinical management in the field of cardio‐oncology and crosses the interface between oncology and onco‐pharmacology. The complexity of the ongoing clinical problem is addressed at different levels. A better understanding of these research‐practice gaps may advance research initiatives on the development of mechanism‐based diagnoses and treatments for the effective clinical management of cardiotoxicity.

show abstract

“…For example, in photoacoustic imaging ( PAI ), pulses of light excite the contrast agent, which in turn produces a mechanical response, detected as ultrasound [61]. Images are obtained noninvasively, deeper within tissues and with higher spatial resolution compared to purely optical imaging techniques.…”

Section: Imagingmentioning

confidence: 99%

Molecular Imaging in Nanotechnology and Theranostics

et al. 2017

View full text Add to dashboard Cite

The “Molecular Imaging in Nanotechnology and Theranostics” (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was founded in 2015 and was officially inaugurated during the 2016 World Molecular Imaging Conference (WMIC). The MINT interest group was created in response to the exponential growth of the fields of Nanotechnology and Theranostics in recent years, and the resulting need to provide a more organized and focused forum on these topics at the WMIS and the WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology, and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nano-constructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3-5 years, in order to provide the reader with an intuition of what is “in the pipeline” and has potential for clinical translation in the near future.

show abstract

What is new in nanoparticle‐based photoacoustic imaging?

Cited by 104 publications

References 74 publications

Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy

Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Molecular Imaging in Nanotechnology and Theranostics

Contact Info

Product

Resources

About